Anticorps Polyclonal de lapin anti-DCK

• Phare
• Validé par KD/KO

DCK Polyclonal Antibody for WB,ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, ELISA

Conjugaison

Non conjugué

Publications

7

N° de cat : 17758-1-AP

Synonymes

DCK, deoxycytidine kinase

---

Galerie de données de validation

• 

  WB analysis using 17758-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 17758-1-AP (DCK antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HeLa using 17758-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 17758-1-AP (DCK antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis of MCF-7 using 17758-1-AP

  MCF-7 cells were subjected to SDS PAGE followed by western blot with 17758-1-AP (DCK antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HepG2 using 17758-1-AP

  HepG2 cells were subjected to SDS PAGE followed by western blot with 17758-1-AP (DCK antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  WB analysis of Jurkat using 17758-1-AP

  Jurkat cells were subjected to SDS PAGE followed by western blot with 17758-1-AP (DCK antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

---

Applications testées

• Résultats positifs en WB: cellules HEK-293T, cellules HeLa, cellules HepG2, cellules Jurkat, cellules MCF-7

Dilution recommandée

• Western Blot (WB): WB : 1:1000-1:3000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 1 publications below
• WB: See 7 publications below

Informations sur le produit

17758-1-AP cible DCK dans les applications de WB, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: DCK Protéine recombinante Ag12123
• Nom complet: deoxycytidine kinase
• Masse moléculaire calculée: 260 aa, 31 kDa
• Poids moléculaire observé: 30 kDa
• Numéro d’acquisition GenBank: BC103764
• Symbole du gène: DCK
• Identification du gène (NCBI): 1633
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Deoxycytidine kinase (dCK) is required for the phosphorylation of several deoxyribonucleoside analogues that are widely employed as chemotherapeutic agents(PMID:12628850). It is also a key enzyme in the phosphorylation of a variety of antineoplastic and antiviral nucleoside analogs including cytosine arabinoside (araC) and dideoxycytidine (ddCyd); deficiency of deoxycytidine kinase activity mediates resistance to these drugs(PMID:1996353). This protein can exsit as a homodimer(PMID:16421443).

Publications

Species	Application	Title
human	WB	Oncogene; KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer.; Authors - Yaoyi Xiong
human	WB	Am J Cancer Res; PMID: 32368394; Authors - Zeng Ye
human	WB	Int J Cancer; Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.; Authors - Nao Yoshida-Sakai
human	WB	Front Oncol; m6A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer.; Authors - Congjun Zhang
human	WB	Invest New Drugs; Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.; Authors - Irene Dell'Anno
human	WB	Sci Rep; Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia.; Authors - Susan K Rathe ; KO Validated